Comparative Pharmacology
Head-to-head clinical analysis: ATRACURIUM BESYLATE versus MIVACRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATRACURIUM BESYLATE versus MIVACRON.
ATRACURIUM BESYLATE vs MIVACRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine binding and causing skeletal muscle relaxation.
Mivacurium is a bis-benzylisoquinoline neuromuscular blocking agent that acts as a competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, leading to muscle paralysis.
0.4–0.5 mg/kg IV bolus for intubation; maintenance: 0.08–0.1 mg/kg IV as needed or infusion 5–10 mcg/kg/min
0.15-0.2 mg/kg IV bolus for intubation; maintenance infusion 9-10 mcg/kg/min
None Documented
None Documented
Terminal elimination half-life is approximately 20 minutes (range 15-25 min) in healthy adults. Clinical context: Recovery from neuromuscular blockade is faster than for nondepolarizing relaxants cleared renally. Half-life may be prolonged in hypothermia or acidosis but is minimally affected by renal or hepatic impairment.
Clinical Note
moderateAtracurium besylate + Tranilast
"Atracurium besylate may increase the neuromuscular blocking activities of Tranilast."
Clinical Note
moderateAtracurium besylate + Tolfenamic acid
"Atracurium besylate may increase the neuromuscular blocking activities of Tolfenamic acid."
Clinical Note
moderateAtracurium besylate + Nimesulide
"Atracurium besylate may increase the neuromuscular blocking activities of Nimesulide."
Clinical Note
moderateAtracurium besylate + Risedronic acid
Terminal elimination half-life is approximately 2-3 minutes; clinically, rapid clearance via plasma cholinesterase results in short duration.
Renal (50-60% unchanged), biliary/fecal (20-30% as metabolites, mainly laudanosine), and Hofmann elimination (non-enzymatic, pH- and temperature-dependent) accounts for approximately 40-50% of clearance.
Primarily renal (approximately 80-90% as unchanged drug and metabolites) and biliary (small fraction, <20% as metabolites).
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker
"Atracurium besylate may increase the neuromuscular blocking activities of Risedronic acid."